Elisenda Climent1, David Benaiges2, Juana A Flores-Le Roux2, Jose M Ramón3, Juan Pedro-Botet2, Albert Goday4. 1. Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona. Campus Universitari Mar, Barcelona, Spain. Electronic address: elisenda.climent.biescas@gmail.com. 2. Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona. Campus Universitari Mar, Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. 3. Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Department of General Surgery, Hospital del Mar, Barcelona, Spain. 4. Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona. Campus Universitari Mar, Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; CiberOBN, Instituto de Salud Carlos III, Madrid, Spain.
Abstract
BACKGROUND: Few studies have compared mid-term results of laparoscopic Roux-en-Y gastric bypass (LRYGB) versus laparoscopic sleeve gastrectomy (LSG), and none have focused on lipid profile. OBJECTIVES: To compare LRYGB versus LSG with respect to lipid disturbance evolution and remission at mid-term after bariatric surgery (BS) and to assess associated factors with the remission of lipid disturbances at 5 years. SETTING: Hospital del Mar, Barcelona, from January 2005 to January 2012. METHODS: A retrospective analysis of a nonrandomized, prospective cohort was conducted on patients undergoing BS at Hospital del Mar, Barcelona, from January 2005 to January 2012 with ≥5 years' follow-up. RESULTS: Of 259 patients, 151 (58.3%) completed the 5-year follow-up. The proportion of patients who achieved normal low-density lipoprotein cholesterol levels at 5 years post-LRYGB was greater than after LSG (30/49 [61.2%] versus 6/23 [26.1%]; P = .005), being male sex, absence of statins treatment, and type of BS technique (LRYGB) the associated factors with remission. Hypertriglyceridemia remission was also higher after LRYGB (23/25 [92.0%] versus 10/15 [66.7%]; P = .041), although type of surgery was not an associated factor. No differences were found in remission rates of low high-density lipoprotein cholesterol between groups. Absence of fibrates treatment and 5-year percentage of excess weight loss were independently associated with hypertriglyceridemia remission, and only the latter was independently associated with low high-density lipoprotein cholesterol remission 5 years after surgery. CONCLUSIONS: Five-year outcome data showed that, among patients with severe obesity undergoing BS, LRYGB was associated with a higher total and low-density lipoprotein cholesterol reduction and remission in comparison to LSG, with no differences in hypertriglyceridemia and high-density lipoprotein cholesterol normalization.
BACKGROUND: Few studies have compared mid-term results of laparoscopic Roux-en-Y gastric bypass (LRYGB) versus laparoscopic sleeve gastrectomy (LSG), and none have focused on lipid profile. OBJECTIVES: To compare LRYGB versus LSG with respect to lipid disturbance evolution and remission at mid-term after bariatric surgery (BS) and to assess associated factors with the remission of lipid disturbances at 5 years. SETTING: Hospital del Mar, Barcelona, from January 2005 to January 2012. METHODS: A retrospective analysis of a nonrandomized, prospective cohort was conducted on patients undergoing BS at Hospital del Mar, Barcelona, from January 2005 to January 2012 with ≥5 years' follow-up. RESULTS: Of 259 patients, 151 (58.3%) completed the 5-year follow-up. The proportion of patients who achieved normal low-density lipoprotein cholesterol levels at 5 years post-LRYGB was greater than after LSG (30/49 [61.2%] versus 6/23 [26.1%]; P = .005), being male sex, absence of statins treatment, and type of BS technique (LRYGB) the associated factors with remission. Hypertriglyceridemia remission was also higher after LRYGB (23/25 [92.0%] versus 10/15 [66.7%]; P = .041), although type of surgery was not an associated factor. No differences were found in remission rates of low high-density lipoprotein cholesterol between groups. Absence of fibrates treatment and 5-year percentage of excess weight loss were independently associated with hypertriglyceridemia remission, and only the latter was independently associated with low high-density lipoprotein cholesterol remission 5 years after surgery. CONCLUSIONS: Five-year outcome data showed that, among patients with severe obesity undergoing BS, LRYGB was associated with a higher total and low-density lipoprotein cholesterol reduction and remission in comparison to LSG, with no differences in hypertriglyceridemia and high-density lipoprotein cholesterol normalization.
Authors: Thinzar Min; Sarah L Prior; Rachel Churm; Gareth Dunseath; Jonathan D Barry; Jeffrey W Stephens Journal: Obes Surg Date: 2020-01 Impact factor: 4.129
Authors: Michelle M C Tan; Xingzhong Jin; Craig Taylor; Adrian K Low; Philip Le Page; David Martin; Ang Li; David Joseph; Nic Kormas Journal: J Clin Med Date: 2022-07-31 Impact factor: 4.964
Authors: Thinzar Min; Sarah L Prior; Gareth Dunseath; Rachel Churm; Jonathan D Barry; Jeffrey W Stephens Journal: Obes Surg Date: 2020-05 Impact factor: 4.129
Authors: David Benaiges; Albert Goday; Juana A Flores-Le Roux; Montserrat Fitó; Oscar Pozo; Jose Rodríguez-Morató; Carme Serra; Manuel Pera; Gemma Llauradó; Elisenda Climent; Olga Castañer; Jose M Ramon; Juan Pedro-Botet Journal: BMJ Open Date: 2020-09-10 Impact factor: 2.692